Laboratorios Salvat, S.a.

Carlos Monserrat Vidal

Carmen Lagunas Arnal

Carles Farrerons Gallemi

Ignacio-Jos&eacute; Miquel Bono

Ana Maria Fernandez Serrat

Andr&eacute;s Fernandez Garcia

Ferran Gimenez Guasch

The invention refers to new compounds of formula (I), wherein A and B are selected from the group consisting of N and CH, with the condition that when A is N, B is N; R is selected from the group consisting of CH and NH ; R and R are selected from the group consisting of H, CH , Br, Cl, COCH and OCH ; and R , R and R , are selected from the group consisting of H, F, Cl, Br, (C1-C3)-alkyl, trifluoromethyl, (C1-C3)-alkoxy and trifluoromethoxy. Compounds of formula (I) are prepared by reaction of a substituted aminoazine with a substituted 2-bromo-2-(4-R -sulfonylphenyl)-1-phenylethanone in a polar solvent. These new compounds inhibit COX-2 with high selectivity over COX-1. They are useful for the treatment of inflamation and/or cyclooxygenase-mediated diseases, having the additional advantage of a reduced potencial for ulcerogenic effects.

Growing community of inventors

Barcelona, Spain

Carlos Monserrat Vidal